From: APOC1 is a prognostic biomarker associated with M2 macrophages in ovarian cancer
Characteristics | Total | Expression of APOC1 | Â | P-value | |
---|---|---|---|---|---|
 |  | High (35) | Low (26) |  | |
Age | Â | Â | Â | Â | |
< 50 | 7 | 5 (71.4%) | 2 (28.6%) | 0.42444 | |
≥ 50 | 54 | 30 (55.6%) | 24 (44.4%) |  | |
FIGO staging | Â | Â | Â | Â | |
I-II | 8 | 5 (62.5%) | 3 (37.5%) | 0.75303 | |
III-IV | 53 | 30 (56.6%) | 23 (43.4%) | Â | |
CA125 | Â | Â | Â | Â | |
< 30.2 | 2 | 2 (100%) | 0 (0%) | 0.21521 | |
≥ 30.2 | 59 | 33(55.9%) | 26(44.1%) |  | |
HE4 | Â | Â | Â | Â | |
< 140 | 13 | 7 (53.8%) | 6 (46.2%) | 0.77195 | |
≥ 140 | 48 | 28 (58.3%) | 20 (41.7%) |  | |
Lymph node metastasis | Â | Â | Â | Â | |
Positive | 32 | 19 (59.4%) | 13 (40.6%) | 0.74014 | |
Negative | 29 | 16 (55.2%) | 13 (44.8%) | Â | |
Greater omentum metastasis | Â | Â | Â | Â | |
Positive | 45 | 26 (57.8%) | 19 (42.2%) | 0.91647 | |
Negative | 16 | 9 (56.3%) | 7 (43.7%) | Â | |
Ascites | Â | Â | Â | Â | |
Positive | 53 | 32 (60.4%) | 21 (39.6%) | 0.22253 | |
Negative | 8 | 3 (37.5%) | 5 (62.5%) | Â | |
BRCA1/2 mutation | Â | Â | Â | Â | |
Positive | 16 | 8 (50%) | 8 (50%) | 0.48707 | |
Negative | 45 | 27 (60%) | 18 (40%) | Â | |
Residual tumor size | Â | Â | Â | Â | |
R0 | 25 | 12 (48%) | 13 (52%) | 0.21717 | |
>R0 | 36 | 23 (63.9%) | 13 (36.1%) | Â |